January 22nd 2010: Sarum Biosciences Limited (“Sarum”) and PBL, the UK technology management company, today announced the signing of an exclusive worldwide licence agreement which enables Sarum to develop and exploit therapeutic and diagnostic applications of a bacteriophage endolysin protein for the treatment and detection of Clostridium difficile, a serious healthcare concern both within the UK and the rest of the world.
